Drug intelligence / Profile preview

SBC-115076

Development stage: Preclinical
Lead developer: Shifa Biomedical
Modality: Small Molecules
Administration: Subcutaneous, Oral

Overview

SBC-115076 is a small-molecule inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) that blocks PCSK9-mediated degradation of the low-density lipoprotein receptor (LDLR), thereby increasing LDLR levels and cellular LDL uptake; it lowers plasma cholesterol in high-fat diet rodent models and has been used as a positive control tool compound in PCSK9 research, remaining at a preclinical research-use stage.

Other names: 1,5-dihydro-3-hydroxy-4-[3-methyl-4-(phenylmethoxy)benzoyl]-1-[3-(4-morpholinyl)propyl]-5-(4-pyridinyl)-2H-pyrrol-2-one

Targets

PCSK9 (Proprotein convertase subtilisin/kexin type 9)

Beyond the preview

Go deeper on SBC-115076.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBC-115076.

Explore the full profile